Lactic acidosis (LA) is a potentially life-threatening complication of antiretroviral (ARV) therapy. Few randomized prospective studies have compared LA between different ARV regimens.
Methods
Characterization of cases of LA (serum lactate >5 mmol/l and arterial pH<7.35 or bicarbonate <20 mmol/l) and symptomatic hyperlactataemia (SH; serum lactate >2.2 mmol/l and symptoms) was made in a randomized open-label 2x2 factorial study of stavudine/lamivudine (d4T/3TC)-based versus didanosine/zidovudine-based therapy and lopinavir/ritonavir-based versus efavirenz (EFV)-based therapy in 1,771 HIV-infected adults initiating therapy between 2004 and 2008.
Results
The LA incident rate was 3.5/1,000 person-years (95% CI 1.8-5.9), and for combined LA/SH was 11.0/1,000 person-years (95% CI 7.9-14.9). There were two deaths (15% mortality) among 13 LA cases; all 11 survivors experienced symptom resolution and started new ARV regimens. LA cases were more likely to be female (OR 7.19, 95% CI 1.84–40.75; P=0.001) and had a higher body mass index (BMI; P<0.0001) compared with non-cases. There was no increase in LA according to ARV regimen, age or CD4+ T-cell count at randomization. When combined, LA/SH cases (n=41) were more often female (OR 4.76, 95% CI 2.36–10.08; P<0.0001), had increased BMI (P<0.0001), were more likely to be assigned d4T/3TC (OR 3.17, 95% CI 1.50–7.28; P=0.001) and were more likely to be assigned EFV (OR 2.18, 95% CI 1.08–4.61; P=0.026).
Conclusions
Female sex and increased BMI were associated with severe LA in this large randomized trial of first-line ARV in South Africa. While female sex, increased BMI and d4T are previously described risk factors for the development of clinically significant lactate elevations, the independent risk associated with EFV is a novel observation warranting further investigation.
References
1.
BolhaarM.G., KarstaedtA.S.A high incidence of lactic acidosis and symptomatic hyperlactatemia in women receiving highly active antiretroviral therapy in Soweto, South Africa. Clin Infect Dis2007; 45: 254–260.
2.
Lactic Acidosis International Study Group.Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy. AIDS2007; 21: 2455–2464.
3.
WesterC.W., OkezieO.A., ThomasA.M.Higherthan-expected rates of lactic acidosis among highly active antiretroviral therapy-treated women in Botswana: preliminary results from a large randomized clinical trial. J Acquir Immune Defic Syndr2007; 46: 318–322.
4.
van GriensvenJ., ZachariahR., RasschaertF., MugaboJ., AtteE.F., ReidT.Stavudine- and nevirapine-related drug toxicity while on generic fixed-dose antiretroviral treatment: incidence, timing and risk factors in a three-year cohort in Kigali, Rwanda. Trans R Soc Trop Med Hyg2010; 104: 148–153.
5.
FortgangI.S., BelitsosP.C., ChaissonR.E., MooreR.D.Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy. Am J Gastroenterol1995; 90: 1433–1436.
6.
GeddesR., KnightS., MoosaM.Y., ReddiA., UebelK., SunpathH.A high incidence of nucleoside reverse transcriptase inhibitor (NRTI)-induced lactic acidosis in HIV-infected patients in a South African context. S Afr Med J2006; 96: 722–724.
7.
ManosuthiW., PrasithsirikulW., ChumpathatN.Risk factors for mortality in symptomatic hyperlactatemia among HIV-infected patients receiving antiretroviral therapy in a resource-limited setting. Int J Infect Dis2008; 12: 582–586.
8.
RatselaA., PolisM., GroupP.I.S., PhidisaI.I.A randomized 2x2 factorial trial comparing initial therapy of efavirenz with lopinavir/ritonavir and zidovudine+didanosine with stavudine+lamivudine in treatment-naive HIV-infected persons with <200 CD4+ cells/mm3 or a prior AIDS diagnosis. J Infect Dis2010; 202: 1529–1537.
9.
YarchoanR., LietzauJ.A., NguyenB.Y.A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection. J Infect Dis1994; 169: 9–17.
ShaferR.W., SmeatonL.M., RobbinsG.K.Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med2003; 349: 2304–2315.
12.
ApostolovaN., Gomez-SucerquiaL.J., MoranA., AlvarezA., Blas-GarciaA., EspluguesJ.V.Enhanced oxidative stress and increased mitochondrial mass during efavirenz-induced apoptosis in human hepatic cells. Br J Pharmacol2010; 160: 2069–2084.
13.
Blas-GarcíaA., ApostolovaN., BallesterosD.Inhibition of mitochondrial function by efavirenz increases lipid content in hepatic cells. Hepatology2010; 52: 115–125.
14.
HoffmannC.J., CharalambousS., FieldingK.L.HIV suppression with stavudine 30 mg versus 40 mg in adults over 60 kg on antiretroviral therapy in South Africa. AIDS2009; 23: 1784–1786.
